Dartibale Camila B, Prado Gabriela de C, Carobeli Lucimara R, Meirelles Lyvia E de F, Damke Gabrielle M Z F, Damke Edilson, Morelli Fabrício, Souza Raquel P, da Silva Vânia R S, Consolaro Marcia E L
Laboratory of Clinical Cytology and Infecções Sexualmente Transmissíveis (ISTs), Department of Clinical Analysis and Biomedicine, State University of Maringá, Maringá, Brazil.
Front Oncol. 2022 Oct 19;12:948471. doi: 10.3389/fonc.2022.948471. eCollection 2022.
Cervical cancer is one of the deadliest cancers among women in Latin America and Caribbean (LAC), where most of the countries have not been successful in implementing population-level cytology-based screening programs. An increasing body of evidence supports the validity of self-sampling as an alternative to clinician collection for primary Human (HPV) screening. Therefore, this work aims to summarize recent HPV self-sampling approaches in LAC.
We performed a systematic review to identify studies focused on "Self-sampling", and "Human Papillomavirus DNA test" and "Latin America" in PubMed, Embase, Web of Science, Cochrane library and SCOPUS databases for publications dating between 01 January 2017 and 15 March 2022 based on the Preferred Reporting Items for systematic reviews and meta-analysis (PRISMA) statement. Additionally, the references of the articles were carefully reviewed.
Of the 97 records selected, 20 studies including 163,787 participants, with sample sizes for individual studies ranging from 24 to 147,590 were included in this review. Studies were conducted in 10 LAC countries (18.5%), most with upper medium-income economies (70%). The range of age was 18 to ≥65 years. The vast majority of the studies (85%) addressed the HPV self-sampling strategy for primary cervical cancer screening with overall success for all women including under/never screened and those from special populations (rural, indigenous and gender minorities). Women generally found HPV self-sampling highly acceptable regardless of age, setting of collection, target population or country of residence.
HPV self-sampling is a promising strategy to overcome the multiple barriers to cervical cancer screening in LAC settings and increasing attendance in underscreened women in countries/territories with well-established screening programs. Furthermore, this strategy is useful even in LAC countries/territories without organized cervical cancer screening and in special populations such as indigenous, rural and transgender women. Therefore, the information generated by the recent initiatives for HPV self-sampling approach in LAC can be beneficial for decision-making in both new and existing programs in the region.
宫颈癌是拉丁美洲和加勒比地区(LAC)女性中最致命的癌症之一,该地区大多数国家在实施基于细胞学的人群筛查项目方面并不成功。越来越多的证据支持自我采样作为初次人乳头瘤病毒(HPV)筛查中临床医生采集样本的替代方法的有效性。因此,本研究旨在总结拉丁美洲和加勒比地区近期的HPV自我采样方法。
我们进行了一项系统综述,以识别在PubMed、Embase、科学网、考克兰图书馆和Scopus数据库中侧重于“自我采样”、“人乳头瘤病毒DNA检测”和“拉丁美洲”的研究,这些研究发表于2017年1月1日至2022年3月15日之间,遵循系统综述和Meta分析的首选报告项目(PRISMA)声明。此外,我们还仔细审查了文章的参考文献。
在所选的97条记录中,本综述纳入了20项研究,包括163787名参与者,单个研究的样本量从24到147590不等。研究在10个拉丁美洲和加勒比地区国家开展(占18.5%),大多数国家为中高收入经济体(占70%)。年龄范围为18岁至65岁及以上。绝大多数研究(85%)探讨了HPV自我采样策略用于原发性宫颈癌筛查,对所有女性总体有效,包括未筛查/从未筛查的女性以及特殊人群(农村、原住民和性别少数群体)。无论年龄、采集地点、目标人群或居住国家如何,女性通常都高度接受HPV自我采样。
HPV自我采样是一种很有前景的策略,可克服拉丁美洲和加勒比地区宫颈癌筛查的多重障碍,并提高在已建立筛查项目的国家/地区中筛查不足的女性的参与率。此外,该策略在没有组织宫颈癌筛查的拉丁美洲和加勒比地区国家/地区以及原住民、农村和跨性别女性等特殊人群中也很有用。因此,拉丁美洲和加勒比地区近期HPV自我采样方法倡议所产生的信息,可能有助于该地区新老项目的决策。